Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy: a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-term outcome of those who relapse after transplant is poor. We present the results of a retros...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2020
|
| In: |
Bone marrow transplantation
Year: 2019, Jahrgang: 55, Heft: 2, Pages: 393-399 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-019-0650-x |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1038/s41409-019-0650-x Verlag: https://www.nature.com/articles/s41409-019-0650-x 
|
| Verfasserangaben: | E. González-Barca, A. Boumendil, D. Blaise, M. Trněný, T. Masszi, H. Finel, M.G. Michieli, J.T. Bittenbring, G. Gritti, J. A. Snowden, M. Bishton, B. Bruno, S. González de Villambrosia, A. Janikova, X. Leleu, A. Anagnostopoulos, X. Poiré, M. Crysandt, Z.N. Özkurt, E. Vandenberghe, M. Itälä-Remes, J.Y. Cahn, E. Jantunen, W. Schroyens, J. Maertens, A. Esquirol, P. Dreger, S. Montoto, A. Sureda |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1692394096 | ||
| 003 | DE-627 | ||
| 005 | 20220818013000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200312r20202019xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-019-0650-x |2 doi | |
| 035 | |a (DE-627)1692394096 | ||
| 035 | |a (DE-599)KXP1692394096 | ||
| 035 | |a (OCoLC)1341310358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a González Barca, Eva |e VerfasserIn |0 (DE-588)1206379774 |0 (DE-627)1692393545 |4 aut | |
| 245 | 1 | 0 | |a Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy |b a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) |c E. González-Barca, A. Boumendil, D. Blaise, M. Trněný, T. Masszi, H. Finel, M.G. Michieli, J.T. Bittenbring, G. Gritti, J. A. Snowden, M. Bishton, B. Bruno, S. González de Villambrosia, A. Janikova, X. Leleu, A. Anagnostopoulos, X. Poiré, M. Crysandt, Z.N. Özkurt, E. Vandenberghe, M. Itälä-Remes, J.Y. Cahn, E. Jantunen, W. Schroyens, J. Maertens, A. Esquirol, P. Dreger, S. Montoto, A. Sureda |
| 264 | 1 | |c 2020 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 20 September 2019 | ||
| 500 | |a Gesehen am 12.03.2020 | ||
| 520 | |a Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-term outcome of those who relapse after transplant is poor. We present the results of a retrospective study of 256 adult patients reported to the EBMT registry with DLBCL who relapsed after auto-HSCT performed between 2003 and 2013, and who received active salvage strategies. One hundred and fifty-four (60%) were male; median age was 53 years. Median time to relapse was 7 months, 65% relapsed during the first year. Overall response rate after salvage therapy was 46%. Median follow-up after first salvage therapy was 40 months (IQR 23-63 months). Overall survival (OS) at 3 years was 27% (95% CI 22-33). OS at 3 years of patients relapsing longer than 1 year after auto-HSCT was 41% (95% CI 31-53) compared with 20% (95% CI 14-24) in those who relapsed in less than 1 year. Eighty-two patients (32%) had a second HSCT, an allogeneic HSCT (allo-HSCT) in 69 cases, at a median time of 6.5 months after relapse. OS at 3 years after allo-HSCT was 36% (95% CI 25-51). In conclusion, the prognosis of patients with DLBCL that relapse after auto-HSCT is dismal. Patients who relapse in less than 1 year remain an unmet need, and should be considered for CAR T cell therapy or clinical trials. Patients who relapse after 1 year can be rescued with salvage therapies and a second HSCT. These results provide a benchmark to compare data of new prospective studies. | ||
| 534 | |c 2019 | ||
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 55(2020), 2, Seite 393-399 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) |
| 773 | 1 | 8 | |g volume:55 |g year:2020 |g number:2 |g pages:393-399 |g extent:7 |a Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-019-0650-x |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-019-0650-x |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200312 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 27 | ||
| 999 | |a KXP-PPN1692394096 |e 3607159777 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"part":{"pages":"393-399","volume":"55","text":"55(2020), 2, Seite 393-399","extent":"7","issue":"2","year":"2020"},"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["Nachgewiesen 19.1997 -"],"language":["eng"],"disp":"Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Bone marrow transplantation","origin":[{"dateIssuedKey":"1997","dateIssuedDisp":"1997-","publisherPlace":"London ; Basingstoke ; London","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group"}],"recId":"320433366","physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Bone marrow transplantation","title_sort":"Bone marrow transplantation"}],"note":["Gesehen am 17.01.25"],"id":{"eki":["320433366"],"zdb":["2004030-1"],"issn":["1476-5365"]}}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["E. González-Barca, A. Boumendil, D. Blaise, M. Trněný, T. Masszi, H. Finel, M.G. Michieli, J.T. Bittenbring, G. Gritti, J. A. Snowden, M. Bishton, B. Bruno, S. González de Villambrosia, A. Janikova, X. Leleu, A. Anagnostopoulos, X. Poiré, M. Crysandt, Z.N. Özkurt, E. Vandenberghe, M. Itälä-Remes, J.Y. Cahn, E. Jantunen, W. Schroyens, J. Maertens, A. Esquirol, P. Dreger, S. Montoto, A. Sureda"]},"physDesc":[{"extent":"7 S."}],"recId":"1692394096","person":[{"role":"aut","family":"González Barca","given":"Eva","display":"González Barca, Eva"},{"family":"Dreger","role":"aut","display":"Dreger, Peter","given":"Peter"}],"id":{"eki":["1692394096"],"doi":["10.1038/s41409-019-0650-x"]},"note":["Published online: 20 September 2019","Gesehen am 12.03.2020"],"title":[{"subtitle":"a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","title_sort":"Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy","title":"Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy"}],"origin":[{"dateIssuedDisp":"2020","dateIssuedKey":"2020"}]} | ||
| SRT | |a GONZALEZBAOUTCOMEINP2020 | ||